![](https://investorshub.advfn.com/uicon/77609.png?cb=1485869477)
Friday, April 15, 2011 2:47:43 PM
MNTA) saw its stock rise more than 5 percent on news that UBS AG equity analysts had initiated coverage on the stock. This despite the fact that the Swiss bank issued an initial Neutral rating with a one-year price target of $17.
The Cambridge, Mass.-based biotechnology company, which launched a successful generic version of Sanofi’s (NYSE: SNY) Lovenox last July, has higher price targets from analysts at Los Angeles-based Wedbush Securities, at $29, and at New York investment banks Rodman and Renshaw and Oppenheimer and Co., Inc., both at $32.
Momenta's stock was trading at $16.57 in afternoon trading Friday, up from $15.69 at the previous close.
Read more: Momenta's stock climbs on UBS coverage | Boston Business Journal
http://www.bizjournals.com/boston/news/2011/04/15/momentas-stock-climbs-on-ubs-coverage.html
FEATURED Element79 Gold Corp. Announces Sale of 100% Interest in Elder Creek, North Mill Creek, and Elephant Projects to 1472886 B.C. Ltd. • Sep 9, 2024 9:34 AM
North Bay Resources Commences Gold Shipments, Fran Gold Project, British Columbia; Enters Taber Gold Mine JV, Sierra County, California • NBRI • Sep 9, 2024 9:15 AM
Simple Stock Loans Announces Unique Solutions For Investors Looking for Alternative Liquidity Amidst Recent Small Cap Rally Sep 6, 2024 9:30 AM
Reliant Coffee Debuts at #271 on the Inc. 5000 List of Fastest Growing Companies - Coffee Service Industry Disruptor Brews Up Exponential Growth Sep 5, 2024 11:51 AM
VAYK Confirms Receiving Revenue from First Airbnb Property with 1.4 Million Annual Revenue Goal • VAYK • Sep 4, 2024 9:34 AM
Mawson Finland Limited Expands Known Mineralized Zones at Rajapalot: New Lens Intercepts 21.75 m at 5.25 g/t Gold & 515 ppm Cobalt • MFL • Sep 4, 2024 9:02 AM